In 2019, we designed our first synthetic nanoparticle vaccine targeting the respiratory virus RSV, a particularly lethal virus for infants and the elderly. Icosavax, an IPD spinout, is now developing this and other vaccine candidates.
We applied this same platform technology to create SKYCovione, a fully-approved COVID-19 vaccine that contains 60 copies of the SARS-CoV-2 Spike protein receptor binding domain. This potent vaccine does not require freezing, a property that should make it easier to reach communities in need.
Efforts are now underway to develop vaccines that protect against a wide range of related influenza and coronaviruses. Such vaccines would provide protection even in the face of new viral variants.